Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Früh

Showing results (441-450 of 552) with videos related to

Pageof 56
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAPRutger D Luteijn, Hanneke Hoelen, Elisabeth Kruse, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
International Journal of STD & AIDS|February 25, 2021
The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in SwitzerlandGalia Santos, Isabella Locatelli, Mélanie Métral, et al.
Heart (British Cardiac Society)|March 25, 2009
Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substratesJ Janousek, R A Gebauer, H Abdul-Khaliq, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2023
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort studyA Schuler, J Huser, S Schmid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
Elife|June 26, 2026
Deciphering interferon functions in avian influenza using receptor knockout models in the natural hostMohanned Naif Alhussien, Hanna Kaisa Vikkula, Romina Klinger, et al.
Pageof 56

Showing results (441-450 of 552) with videos related to

Sort By:
Pageof 56
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAPRutger D Luteijn, Hanneke Hoelen, Elisabeth Kruse, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
International Journal of STD & AIDS|February 25, 2021
The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in SwitzerlandGalia Santos, Isabella Locatelli, Mélanie Métral, et al.
Heart (British Cardiac Society)|March 25, 2009
Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substratesJ Janousek, R A Gebauer, H Abdul-Khaliq, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2023
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort studyA Schuler, J Huser, S Schmid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
Elife|June 26, 2026
Deciphering interferon functions in avian influenza using receptor knockout models in the natural hostMohanned Naif Alhussien, Hanna Kaisa Vikkula, Romina Klinger, et al.
Pageof 56